A study recently published in BMC Psychiatry found that antipsychotic dosage reduction in patients with bipolar and major depressive disorders was associated with an increase in all-cause and mental health-related hospitalizations.
Adjunctive esketamine appears effective for patients with major depressive disorder (MDD) who are treatment-resistant or suicidal, a meta-analysis published in The Journal of Clinical Psychiatry concluded.
A novel vasopressin 1B (V1B) receptor antagonist eased depressive symptoms when used as an adjunctive treatment in patients with major depressive disorder (MDD) in a small phase 2 study in the Journal of Psychiatric Research.
The US Food and Drug Administration (FDA) recently granted Usona Institute, Madison, Wisconsin, the Breakthrough Therapy designation for psilocybin in the treatment of patients with major depressive disorder (MDD).
SAN DIEGO—Mental health clinicians aren't talking to their patients enough about sexual dysfunction commonly associated with depression and its treatment, Anita Clayton. MD, stated at Psych Congress 2019.
SAN DIEGO—Added to standard-of-care treatment, esketamine nasal spray rapidly reduced depressive symptoms in patients at imminent risk of suicide, according to two phase 3 trials presented at Psych Congress 2019.